Kanna has a 2,000+ year history of human use in southern Africa with no documented deaths attributed to kanna alone and a favorable safety profile in clinical research. The two main clinical trials on standardized kanna extract (Zembrin®) — published in 2013 and 2014 — found no serious adverse events at 25mg doses. The primary safety concern with kanna is its serotonin reuptake inhibition: combining kanna with serotonergic medications (SSRIs, SNRIs, MAOIs, tramadol, certain migraine medications) creates serotonin syndrome risk — a potentially serious condition characterized by agitation, tremor, hyperthermia, and in severe cases, seizure. Outside of drug interactions, kanna at standard doses is considered low-risk for most healthy adults. Raw powder has more variability in alkaloid content than standardized extracts, making dosing less predictable.

What are kanna's side effects?

At doses consistent with research (25–50mg standardized extract) and moderate recreational use (200–400mg raw powder), kanna's side effects are mild: headache, nausea, and appetite suppression are the most commonly reported. At high doses (100mg+ standardized, 1g+ raw powder), effects shift toward strong euphoria, sedation, and in some users, mild dissociation. Very high doses historically used by traditional shamans (multiple grams of fermented plant material) can produce more intense effects, but these are outside the range of typical modern use. Kanna has no documented addictive profile in the clinical literature, and no well-characterized withdrawal syndrome has been described.

Can you overdose on kanna?

No documented fatal kanna overdoses exist in the medical literature. Kanna's serotonin syndrome risk (from combination with other serotonergic drugs) is the most serious potential adverse event, but this is an interaction effect, not a kanna-only overdose risk. Very high doses of kanna alone produce uncomfortable sedation, nausea, and possibly strong dissociation, but self-limiting effects (nausea) discourage extreme dosing. The 2,000-year history of use without fatalities in traditional contexts, combined with favorable clinical trial safety data, places kanna in a low-risk category relative to most psychoactive substances.

Who should not use kanna?

People who should avoid kanna: (1) Anyone taking SSRIs, SNRIs, MAOIs, or other serotonergic medications — serotonin syndrome risk. (2) Anyone with serotonin syndrome history. (3) People with bipolar disorder — serotonin-active substances can trigger manic episodes. (4) Pregnant or breastfeeding individuals — no safety data in pregnancy. (5) People with severe cardiovascular conditions — though kanna has minimal cardiovascular effects compared to stimulants, caution is appropriate. For everyone else, kanna at standard doses is a low-risk botanical. Find kanna at Elevated Haze.